Podcasts about sabbagh

Comment connecter le “vrai” inventaire des tours-opérateurs au web… et réparer la vente de voyages en ligne ? C'est le pari de Christian Sabbagh avec Travelsoft.Mais l'histoire commence bien avant la techno. Elle commence à Beyrouth, où Christian vit dix ans de guerre avant d'atterrir en France pour passer le bac.Dix ans de conseil plus tard, il se lance sans “idée géniale”, avec deux mots sur la table, internet et tourisme, et l'envie de jouer avec.Les premières années, ce n'est pas glamour : des nuits longues, du code, des intégrations serrées et une obsession simple, vendre en ligne ce qui existe vraiment, au bon prix, sans promesse fantôme.La plateforme prend, les clients suivent, mais l'entreprise reste fragile. C'est alors qu'arrive une offre de rachat.Sur le papier, tout le monde respire. Sauf lui. Christian voit le risque d'intégration, la petite boîte qui se dissout dans un très grand ensemble, les arbitrages qui s'éloignent du client. Alors il dit non. S'ensuivent des mois tendus, où il faut à la fois tenir l'opérationnel et réorganiser la cap table : faire sortir immédiatement les investisseurs historiques, faire entrer de nouveaux partenaires, et surtout garder la main.Ce pari d'indépendance ouvre un nouveau chapitre : redevenir progressivement majoritaire. Et là, tout s'accélère. La majorité permet d'aller plus vite, de prendre des risques calculés, de choisir un build-up patient plutôt qu'une uniformisation brutale.L'Allemagne, puis d'autres marchés ; des acquisitions où l'on laisse de l'autonomie à ceux qui créent de la valeur ; des packages cash / earn-out / equity pensés pour aligner les fondateurs sur la durée.Résultat : d'une entreprise très française, Travelsoft devient un champion européen du logiciel touristique, employant 700 personnes, 120 M€ de CA, et 40 Md€ de volumes dans 80+ pays.La part de la France n'est plus aussi massive ; le client, lui, pèse toujours 100 %.Aujourd'hui, Christian regarde déjà le prochain virage : l'IA qui transforme la recherche et la découverte de voyages, des interfaces conversationnelles qui captent la demande et exigent d'être branché au bon niveau.Son style n'a pas changé : minimiser le négatif, célébrer les petites victoires, et répéter le geste juste, celui qui garde la promesse faite au marché.Travelsoft s'est construit comme ça : en disant non au confort à court terme pour dire oui à la liberté d'exécuter sur le long terme.À l'animation :Thomas Benzazon, cofondateur de FeuilleBlancheKarine Wilkinson, Managing Director chez PictetUn podcast conçu par FeuilleBlanche, producteur de médias, podcasts et récits stratégiques pour les marques.À vos écouteurs

ELECTION 2025 - GEORDIE SABBAGH LIBERAL

Welcome to episode 688. We have one tale for you this week, about a company with ancient roots who serves some very thirsty clients.COMING UPGood Evening: 00:01:06Jason Sabbagh's The Last Fare to Essex as read by Graeme Dunlop: 00:02:40PERTINENT LINKSSupport us on Patreon! Spread the darkness.Shop Tales to Terrify MerchGraeme Dunlop | PodcastleGraeme Dunlop on Twitter (@kibitzer)Original Score by Nebulus EntertainmentNebulus on FacebookNebulus on InstagramSPECIAL THANKS TOAmanda CarrilloLestle BaxterOrion D. HegreSupport this show http://supporter.acast.com/talestoterrify. Hosted on Acast. See acast.com/privacy for more information.

Idée reçue : les problèmes de diversité génétique sont souvent assimilés aux petits races, ce qui est loin d'être le cas. Au travers de ce podcast, Margot Sabbagh, ingénieure de projets & développement génétique des équidés à l'IFCE, va nous expliquer les différentes notions essentielles pour bien comprendre les problématiques associées à la gestion de la diversité génétique. Les outils en lien avec la consanguinité, les ancêtres majeurs et la composition raciale seront abordés pour vous aider à mieux les intégrer dans le raisonnement de vos croisements.Pour aller plus loin :• Articles équipédia - Génétique• Articles équipédia - Variabilité génétique• Webconférence - Diversité génétique des races locales françaises• Outil de simulation - Coefficient de consanguinité• Webconférence - Consanguinité : comment la calculer ?Si vous souhaitez en savoir plus sur le sujet, rendez-vous sur notre site internet equipedia.ifce.fr où vous trouverez tous les travaux de nos experts. Vous pouvez aussi nous rejoindre sur notre groupe Facebook équipédia, sciences et innovations équines pour plus de contenus. Pour ne manquer aucun épisode, abonnez-vous, partagez, commentez et n'hésitez pas à laisser 5 étoiles sur Apple Podcasts et Spotify.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

IRAN: Countdownt: Ray Takeyh is Hasib J. Sabbagh senior fellow for Middle East studies at the Council on Foreign Relations (CFR). His areas of specialization are Iran, U.S. foreign policy, and modern Middle East. Malcolm Hoenlein @Conf_of_pres @mhoenlein1 1849 TEHRAN

GOOD EVENING: The show begins tonight in Ukraine where the news is of a cross-border assault by Kyiv into Russia, and a report of a pending big push by Russia into Ukraine's defenses -- readying for talks to cut up the map. 1935 San Diego CBS EYE ON THE WORLD WITH JOHN BATCHELOR FIRST HOUR 9-915 #UKRAINE: Big Russian push October. Anatol Lieven, Quincy Institutehttps://eadaily.com/en/news/2024/08/06/the-united-states-gave-61-billion-to-kiev-to-win-but-they-didnt-say-how-because-you-dont-have-to 915-930 #IRAN: Shoigu in Tehran, and why? Anatol Lieven, Quincy Institutehttps://eadaily.com/en/news/2024/08/06/the-united-states-gave-61-billion-to-kiev-to-win-but-they-didnt-say-how-because-you-dont-have-to 930-945 #SCALAREPORT: China's two-year-long recession continues and deepens. Chris Riegel CEO, Scala.com @Stratacache https://www.msn.com/en-ca/money/topstories/maersk-expects-container-demand-growth-to-slow-raises-investment-forecast/ar-AA1oo6EA 945-1000 #VENEZUELA: Maduro tries lawfare and terror. Mary Anastasia O'Grady, WSJhttps://www.wsj.com/articles/lula-assists-the-maduro-steal-brazil-presidential-election-27a9cb50 SECOND HOUR 10-1015 IRAN: Countdown: Ray Takeyh is Hasib J. Sabbagh senior fellow for Middle East studies at the Council on Foreign Relations (CFR). His areas of specialization are Iran, U.S. foreign policy, and modern Middle East. Malcolm Hoenlein @Conf_of_pres @mhoenlein1 1015-1030 RUSSIA: Shoigu in Tehran and why? John Hardie serves as deputy director of FDD's Russia Program. His research focuses on Russian foreign and security policy, U.S. policy toward Russia and the post-Soviet space, and transatlantic relations. Malcolm Hoenlein @Conf_of_pres @mhoenlein1 1030-1045 #Antisemitism: Dr. Alan Mendoza is the founder and executive director of the Henry Jackson Society, a UK-based foreign and security policy think tank. Malcolm Hoenlein @Conf_of_pres @mhoenlein1 1045-1100 #ISRAEL: Routinely reported. Jonathan Conricus is a senior fellow at FDD focused on the Middle East. He served in the Israel Defense Forces (IDF) for 24 years as a combat commander in Lebanon and the Gaza Strip. He also served as a military diplomat, foreign relations expert, and international spokesperson. Malcolm Hoenlein @Conf_of_pres @mhoenlein1 THIRD HOUR 1100-1115 #NAGASAKI: Charles Sweeney knew of the schools and church in the target area. Charles Pellegrino, author, LAST TRAIN FROM HIROSHIMA. [Amazon links removed for brevity] 1115-1130 #NAGASAKI: The burning horses. Charles Pellegrino, author, LAST TRAIN FROM HIROSHIMA. [Amazon links removed for brevity] 1130-1145 #VPOTUS: Tim Walz from Tiananmen Square to the Dalai Lama. Josh Rogin, Washington Post.https://www.washingtonpost.com/opinions/2024/08/08/walz-harris-campaign-china-experience/ 1145-1200 #IRAN: What does the Ayatollah want with his threats? Behnam Ben Taleblu, FDD https://www.msn.com/en-us/news/world/us-warns-iran-of-serious-risk-if-it-conducts-major-attack-on-israel/ar-AA1otb4u FOURTH HOUR 12-1215 #NewWorldReport: Venezuela: The Opposition in hiding from the regime. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @revanellis #NewWorldReportEllishttps://www.reuters.com/world/americas/venezuela-launches-criminal-probe-into-publishers-election-tally-website-2024-08-07/ 1215-1230 #NewWorldReport: The guys with the guns pledge loyalty to Maduro. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @revanellis #NewWorldReportEllishttps://www.reuters.com/world/americas/venezuela-launches-criminal-probe-into-publishers-election-tally-website-2024-08-07/ 1230-1245 #NewWorldReport: Brazil, Colombia and Mexico hesitate. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @revanellis #NewWorldReportEllishttps://www.reuters.com/world/americas/venezuela-launches-criminal-probe-into-publishers-election-tally-website-2024-08-07/ 1245-100 am #NewWorldReport: The worst Amazon fires in two decades. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @revanellis #NewWorldReportEllishttps://www.reuters.com/business/environment/fires-brazils-amazon-rainforest-july-surge-highest-two-decades-2024-08-01/

Let's celebrate. This is episode 100! My guest is Jonathan Sabbagh, Co-Founder of Journey Clinical and I talk about normalising Ketamine therapy for all, plus why PTSD can fire up your career - until you realize it is harmful to you. Since a few years I am following Jonathan and his wife and Co-Founder Myriam Barthe's great work around the idea to build a strong, decentralized network and offerings for KAP (Ketamine Assisted Psychotherapy) to empower as much therapists as possible to execute the therapy. They did an incredible and successful job to make Ketamine therapy available and build a strong system in collaboration with therapists and doctors.In this episode is talk to Jonathan about: -how PTSD can give you a skyrocketing career, until you realiize your “energy” is trauma in disguise-how we both were very good in PTSD friendly jobs (banking & media) and left them because we realised our own PTSD -how Journey Clinical helps therapists to support their patients with ketamine therapy, (eventually psilocybin) if they are interested in trying and why normal “therapy” needs a strong transformation What Journey Clinical doesJourney Clinical is on a mission to transform the growing mental health crisis by accelerating the mainstream adoption of legal, evidence-based Psychedelic-Assisted Psychotherapy as the standard of care for mental health, starting with Ketamine-Assisted Psychotherapy. They have built a leading platform for Psychedelic-Assisted Psychotherapy in the US. They also recently announce a research collaboration agreement with Compass Pathways to inform the development of a scalable delivery and training model for COMP360 psilocybin treatment. Which means, together with Compass, they work on a future delivery model for psilocybin therapy. INFO@journeyclinical @Jonathansabbaghwww.https://www.journeyclinical.com/. Hosted on Acast. See acast.com/privacy for more information.

Une histoire écrite par Clémence Sabbagh et illustrée par Magali Le Huche aux éditions Les fourmies rouges , interprétée par Céline Kallmann, réalisation et musique Alexandre Ferreira, production Benjamin Muller.    Musiques : Vlad Gluschenko - Time / Alexandre Ferreira.  Retrouvez Encore une histoire sur Instagram, Facebook et Twitter. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Dietitian, Trainer, Adidas Athlete and Health Expert Baraa El Sabbagh Joins me in Dubai to open up about new motherhood, parenting and the ways you can love your body and connect with the world around you after becoming a new parent. Baraa also has great tips on how we can give our bodies all the best tools of true self care. You don't have to lose your identity as a new parent! Here are great ways you can stay connected with your truest self. Host @naila Guest @baraaelsabbagh Get Baraa's health program here : https://offers.baraaelsabbagh.com/ --- Support this podcast: https://podcasters.spotify.com/pod/show/naila-nazer/support

Physician burnout is an important issue impacting healthcare across the country. Join us as we hear from Habib Sabbagh, the Physician Wellness Program Manager at a large West Coast academic medical center! Hear his insights on the magnitude of this issue, how organizations can go about tackling it, and some resources to get started.

Welcome back everybody for this latest Audio Excursion! Saxophonist Jerome Sabbagh is my guest, and is the founder of Analog Tone Factory - a new record label that records exclusively to analog tape! Coming at this project as a musician himself, Jerome has taken up the mantle for high quality recording techniques to aid the purists among us for the highest quality audio reproduction. As their website states: "no computers were harmed in the making of our records:. Join us for the story of his journey in bringing this record label to life in 2024!   For more information on host David Bianco: https://www.youtube.com/@SafeAndSoundTXAudioExcursion   For more information on Jerome Sabbagh and Analog Tone Factory: https://www.jeromesabbagh.com https://www.analogtonefactory.com   For more information on Vinyl Community Podcasts: https://vinylcommunitypodcasts.com  

Sarabraj “Sarab” S. Thapar is a Certified Civil Trial Attorney, an honor held by only 2% of attorneys. In order to achieve this distinction, Sarab had to complete a specific number of trials, receive recommendations from judges and other attorneys, and pass a written test to demonstrate his knowledge. He is licensed in both New Jersey and New York. What sets Sarab apart is his prior experience representing defendants, which offers him a unique insight into the strategies and tactics employed by the defense. Sarab has handled a wide array of matters including motor vehicle, motorcycle and trucking accidents, as well as bus, train, and numerous Uber/Lyft crashes. He has also represented several bicyclists and pedestrians who were struck by vehicles. Additionally, Sarab has successfully assisted clients recover money in slip and fall incidents on both public and private premises, as well as victims of dog attacks/bites. Sarab has been able to recover millions of dollars for his clients by way of settlement or trial. With an over 90% success rate at trial, Sarab is well-regarded as a keen litigator amongst his peers and clients. Sarab has qualified and been accepted into the Million Dollar Advocates, New Jersey Super Lawyers' Rising Stars list every year since 2017, Top 10 Under 40 in Personal Injury, and a recipient of the award for Lawyers of Distinction's Excellence in Civil Litigation. Sarab was also named Young Lawyer of the Year by SABA-NJ. During law school, Sarab interned for the Hon. Donald J. Venezia, J.S.C. where he gained valuable experience handling criminal matters. He was previously the Public Advocate for the Township of West Orange. Linkedin: ⁠https://www.linkedin.com/in/sarab-thapar-esq-02760718/ Sabbagh Thapar: ⁠https://sabbaghthapar.com/ Learn more about EmotionTrac and our AI-driven Emotional Intelligence Platform: ⁠https://legal.emotiontrac.com/

Bassam and Cat rekindle their Artist Forge connection and dig into his discovery of photography and spending a year mastering his skillsets in lighting, and posing,  and upon his completion of that first year (2016) he exited his career as a VP in Aerospace. Bassam maintained a consultancy arm to stay connected in that industry for small and medium businesses but dove in headfirst in building his portrait business after assisting a friend on their photo shoot and discovering the joy that comes in photography. He was hooked on day one and hasnt looked back since!As things happen and unfold once a decision is made, Bassam rented a shared studio space, spent a year portfolio building, and made connections within the industry with Pratik Naik, Bella Kotak, Sue Bryce and more. Bassam and Cat recap the milestones of his career as a portrait photographer and then they go even deeper into challenges as a male boudoir photographer (challenges in marketing) and address the sales process to encourage larger sales. Bassam has consistently been selling his largest package (what a problem to have right?) but within this conversation he and Cat uncovered an area where he may have been leaving money on the proverbial table. This conversation is not to be missed!Bassam is such a brilliant business mind and paired with his artistry is a force! Make sure you follow and connect with Bassam below.Website: www.kuriousphoto.comIG: @bassam.sabbagh.photography and @kuriousboudoir Are you a Photographer? Maybe a wedding photographer who is getting burnt out and wants to transition into portrait? Or simply a photographer who loves portraits but doesn't quite know how to build a thriving business? Maybe I can help. Book a complimentary 1:1 call to assess where you are currently and where you're going. If we decide it's a good fit I may invite yui to one of our programs or simply offer resources that can help. https://calendly.com/828avl/studio-takeover-1-1

Steven Cook, the Eni Enrico Mattei Senior Fellow for Middle East and Africa Studies at CFR, and Ray Takeyh, the Hasib J. Sabbagh senior fellow for Middle East studies at CFR, sit down with James M. Lindsay to discuss Iran's unprecedented attack on Israel and the prospects for a broader Middle East war.   Mentioned on the Episode    Steven A. Cook, "Iran Attack Means an Even Tougher Balancing Act for the U.S. in the Middle East," CFR.org   Steven A. Cook, The End of Ambition: America's Past, Present, and Future in the Middle East [forthcoming]   Reuel Marc Gerecht and Ray Takeyh, “Keeping U.S. Power Behind Israel Will Keep Iran at Bay,” New York Times   Ray Takeyh, "Iran Attacks on Israel Spur Escalation Concerns," CFR.org   Ray Takeyh, The Last Shah: America, Iran, and the Fall of the Pahlavi Dynasty   For an episode transcript and show notes, visit The President's Inbox at: https://www.cfr.org/podcasts/irans-attack-israel-steven-cook-and-ray-takeyh 

Le ramadan, ce mois de jeûne musulman ponctué de moments de partage festifs et joyeux à l'heure de l'iftar, le repas du soir, a un goût très amer cette année dans la bande de Gaza. Cinq mois se sont écoulés depuis le début de l'offensive israélienne, le 7 octobre, en riposte à une attaque sans précédent du Hamas sur le sol israélien qui a fait au moins 1160 morts, selon un bilan réalisé par l'AFP à partir de source officielle. Dans la bande de Gaza, au moins 31.000 personnes ont été tuées selon le gouvernement du Hamas et les bombardements se poursuivent.Et l'ONU, tout comme les ONG d'aide humanitaire multiplient les avertissements sur les conséquences du conflit. Les 2,4 millions d'habitants du territoire sont menacés par la famine, alors que l'aide n'arrive qu'au compte-goutte et que des kilomètres de camions remplis d'aide restent bloqués. Pour ce Sur le Fil nous vous proposons d'écouter deux humanitaires qui viennent de rentrer de la bande de Gaza, Jean-Pierre Delomier, d'Handicap International et Louise Bichet, de Médecins du monde. Et de parler de la solution, qui pourrait passer par des changements politiques en Israël.Avec : Marc Jourdier, directeur du bureau de l'AFP à Jérusalem et sur le terrain nos cinq journalistes dans la bande de Gaza : Adel Zaanoun, en texte, en photo Mohammed Abed et Said Khatib, et pour la video Bilal al Sabbagh et Yahya Hassouna.Réalisation: Michaëla Cancela-KiefferSur le Fil est le podcast quotidien de l'AFP. Vous avez des commentaires ? Ecrivez-nous à podcast@afp.com. Vous pouvez aussi nous envoyer une note vocale par Whatsapp au + 33 6 79 77 38 45. Si vous aimez, abonnez-vous, parlez de nous autour de vous et laissez-nous plein d'étoiles sur votre plateforme de podcasts préférée pour mieux faire connaître notre programme ! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In this episode, I interviewed Dr. Ubadah Sabbagh & Dr. Daniel Gonzales. Ubadah is a Syrian neuroscientist and NIH K00 Fellow at the McGovern Institute for Brain Research at MIT, and Daniel just started a faculty position at Vanderbilt University in the Department of Biomedical Engineering. They met over social media, are freakin' HILARIOUS, and I am so glad I got to put them together in a Zoom room! --- Send in a voice message: https://podcasters.spotify.com/pod/show/fromwheredoesitstem/message

Pour le raisin, il y a une vie après le vin! Un alambic ambulant qui s'arrête dans les villages mythiques de Bourgogne et distille sur place les marcs de pinot noir et de chardonnay issus des plus grands domaines pour en faire des eaux-de-vie sublimes: bienvenue chez Sab's !À l'origine de ce projet, Mathieu et Amélie Sabbagh nous racontent leur histoire et nous font gouter certains de leurs flacons incroyables: Marcs de Bourgogne, Fines, mais aussi des gins et d'autres créations originales.Quand la tradition ancestrale est revisitée avec passion et créativité!Hosts: Alessandra Fottorino Patrice Defay, Romain Corler Générique: Easy LivingEnregistré au Studio Module Retrouvez-nous sur Instagram, Facebook

Today's guest is Ray Takeyh, senior fellow for Middle East studies at the Council on Foreign Relations, and a former senior advisor on Iran at the State Department. In this episode, we discuss the mindset of the Iranian regime and what the US' understanding of it may be, the so-called ‘axis of resistance' and Iran's use of proxies in various regional conflicts, and how that regional involvement is impacting the Israeli-Palestinian conflict and the current war in Gaza. Full bio Ray Takeyh is Hasib J. Sabbagh senior fellow for Middle East studies at the Council on Foreign Relations (CFR). His area of specialization are Iran, U.S. foreign policy, and modern Middle East. Takeyh is, most recently, the author of The Last Shah: America, Iran and the Fall of the Pahlavi Dynasty. He is the coauthor of The Pragmatic Superpower: Winning the Cold War in the Middle East and Revolution & Aftermath: Forging a New Strategy toward Iran. He is author of three previous books, Guardians of the Revolution: Iran and the World in the Age of the Ayatollahs, Hidden Iran: Paradox and Power in the Islamic Republic, and The Origins of the Eisenhower Doctrine: The US, Britain and Nasser's Egypt, 1952-1957. He has written more than three hundred articles and opinion pieces in many news outlets including Wall Street Journal, New York Times, and Foreign Affairs. Takeyh has testified more than twenty times in various Congressional committees. Prior to joining CFR he has served as a senior advisor on Iran at the State Department, fellow at the Yale University, Washington Institute of Near East Policy and Middle East Center at University of California, Berkeley. Takeyh has a doctorate in modern history from Oxford University.

Ray Takeyh, the Hasib J. Sabbagh senior fellow for Middle East studies at CFR, and Robin Wright, a contributing writer and columnist for the New Yorker, sit down with James M. Lindsay to discuss the ramifications of U.S. retaliation against Iranian-backed militias after the killing of three U.S. service members in Jordan on January 28.   Mentioned on the Episode    Ray Takeyh, The Last Shah: America, Iran and the Fall of the Pahlavi Dynasty   Robin Wright, Rock the Casbah: Rage and Rebellion Across the Islamic World   For an episode transcript and show notes, visit The President's Inbox at:  https://www.cfr.org/podcasts/us-airstrikes-iraq-and-syria-ray-takeyh-and-robin-wright 

Le 10 janvier 2024, la Securities and Exchange Commission (SEC) a donné son approbation pour les premiers ETF Bitcoin spot ! Plus de 10 ans après la première demande officielle, c'est désormais officiel. Il est l'heure de se questionner ensemble sur l'impact de cet événement sur l'avenir du BTC avec Cyril Sabbagh, managing director à Melanion Capital, créateur du premier ETF UCITS au monde sur la thématique Bitcoin.

"First thing you need to connect the assets first and get the data. So that's we call it like static digital twin, and then you can use it for simulation. Then you move to the second version, which having like a shadow, digital twin, which you have an image of what's happening, but you can monitor. But the truly digital twin is monitor and control." In this episode, I'm in conversation with Ammar Sabbagh who is the Vice President Industry and Partnership for Private Networks for Oil and Gas at Ericsson. 5G networks are a huge step forward for telecommunications, offering a step change performance boost over 4G. If you want to run an industrial-grade, resilient, and secure network for your digital devices, you need to be on 5G.  Here are some of the key questions addressed in the episode:  What is 5G, and why is it better than 4G? What is a private network?  What kinds of problems does a private network solve? What kinds of innovations are enabled by 5G? What are some of the use cases that 5G unlocks? How do you deliver 5G networks where there are no towers? Ammar Sabbagh is a technology professional specializing in 5G private cellular networks, cloud, decentralized cloud, and IOT solutions for business and industry. Currently, Ammar serves as vice president of industry & partnership at Ericsson for energy and ports, where he leads business development and global partners management. Ammar holds a BS in Electrical Engineering from Portland State University and an MBA in Management, and has completed various executive leadership training courses, including Design Thinking for Innovation from the London Business School. AMMAR's QUOTABLE QUOTES  With 4g, you're getting 100 megabits per second. With 5G you are getting one gigabit per second and even 20 gigabits pers second planned for next year or after. So 20 gig per user device. A single 5G radio station can connect over a million connected devices at one radio station.  With WiFi 6, you can stream one gig, but the reliability of the Wi Fi is a concern, because Wi FI struggles to penetrate metallic structure [common] in the industry, for indoor. You can trust 5G for robotics, for autonomous gantry vehicles, for assets moving. With 5G we are not planning to replace any [SCADA] wiring. 5G [latency] operation, we are talking about 20 millisecond max. We are dropping it to one millisecond in the next version updates… But the requirements from our Oceaneering partner is only 100 millisecond. The first question we ask what are the use cases or application you want to use? And then it's a journey. It's like you start today with one thing, and later, you move to other applications as needed. If you have a worker with a mobile phone or connected, you know, worker, you will know exactly where they are. And you can communicate with them and support them during that session. We like to call it dynamic  digital twin. We believe the 5g will be you know, hugely valuable, because you don't want to run all these cables connecting all these sensors to the main data center, you're just wirelessly spread them. And they're connected, and sit and analyze and collect all the data and take actions from there. Wind turbines are virtually autonomous. I mean, we connect them with cellular network, we have several references. With a cellular network, they connect the operator connect cameras and control functionality. And they remotely see what's happening on the outside and inside and adjust accordingly. first thing you need to connect the assets first and get the data. So that's we call it like static digital twin, and then you can use it for simulation. Then you move to the second version, which having like a shadow, digital twin, which you have an image of what's happening, but you can monitor. But the truly digital twin is monitor and control CONTACTING AMMAR ammar.sabbagh@ericsson.com

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon.

The key to understanding Alzheimer's disease could be in our genes. While the cause of Alzheimer's is still unknown, mounting research shows that carrying multiple copies of certain genes — like genetic variant ApoE4 — can significantly increase the likelihood of developing Alzheimer's. By studying genetics and gene therapy, scientists are learning more about how genes play a role in Alzheimer's disease and what can be done for prevention. Barrow Neurological Institute's neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient to discuss how scientists are seeking to prevent Alzheimer's through genetic research. Sabbagh, a board-certified behavioral neurologist at Barrow's Alzheimer's and Memory Disorders Program and a professor at the institute's department of neurology, has served as the lead investigator on several prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak about how genetic research, like that on the ApoE4 gene, can help us learn more about Alzheimer's and how it can be prevented. This Live Talk is sponsored by Alzheon. Watch now to learn more about the genetics of Alzheimer's disease. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia.

To gain a deeper understanding into today's conflicts within the Middle East, our focus sharpens on two pivotal forces: Iran and Saudi Arabia, whose roles hold paramount significance in shaping the region's contemporary landscape. This week host Elisa revisits two key conversations from our archive. First, Dr. Roham Alvandi of the London School of Economics and Political Science discusses the shift in Iran's governing structures from the coup in 1953 to the revolution in 1979. Next, Ray Takeyh of the Council on Foreign Relations dives into the fall of the Pahlavi dynasty and how the 1979 Iranian Revolution marked a critical turning point in US-Iran relations. Dr. Roham Alvandi is Associate Professor of International History at the London School of Economics and Political Science: https://www.lse.ac.uk/international-history/people/academicstaff/alvandi/alvandi Ray Takeyh is Hasib J. Sabbagh senior fellow for Middle East studies at the Council on Foreign Relations: https://www.cfr.org/expert/ray-takeyh References: NSLT Ep. 231, Iran Series: Coups and the Cold War Era with Dr. Roham Alvandi (Part 1): https://podcasts.apple.com/us/podcast/national-security-law-today/id1276946676?i=1000588399346 NSLT Ep. 229, Iran Series: The Rise of the Islamic Republic with Ray Takeyh (Part 1): https://podcasts.apple.com/us/podcast/national-security-law-today/id1276946676?i=1000585769361 Alvandi, Roham. Nixon, Kissinger, and the Shah the United States and Iran in the Cold War. Oxford University Press, 2016: https://global.oup.com/academic/product/nixon-kissinger-and-the-shah-9780190610685?prevSortField=9&q=*&resultsPerPage=100&lang=en&cc=gb# Alvandi, Roham. The Age of Aryamer: Late Pahlavi Iran and Its Global Entanglements. The Gingko Library, 2018: https://www.gingko.org.uk/publishing/books/the-age-of-aryamehr/?fbclid=IwAR0Xbu7sDHE8wbin2QUeMxaAfVMa32U24FUrsUY3FEScx3XPFM_NzgOfrVQ Takeyh, Ray. The Last Shah: America, Iran, and the Fall of the Pahlavi Dynasty. Yale University Press, 2021: https://yalebooks.yale.edu/book/9780300264654/the-last-shah/

atching and accurately identifying a neurodegenerative disease like Alzheimer's or another form of dementia early can make all the difference in the world to a patient and their loved ones: An early diagnosis means more time to plan for the future, join a clinical trial testing cutting-edge disease-modifying treatments, making lifestyle changes to slow symptoms, or spending more time with loved ones. On the other hand, a misdiagnosis could mean that patients receive the wrong medications, causing harm — and unfortunately misdiagnoses are all too common when it comes to dementia. Why is this the case, and what can patients do about it? Neurologist, author, and Alzheimer's expert Dr. Marwan Sabbagh joins Being Patient Live Talks to discuss why dementias are so difficult to diagnose. Sabbagh, a board-certified behavioral neurologist at Barrow Neurological Institute's Alzheimer's and Memory Disorders Program and a professor at the institute's Department of Neurology, has served as the lead investigator on a number of prominent national Alzheimer's prevention and treatment clinical trials. In this talk, he'll speak to the factors that make dementia so difficult to diagnose accurately for experts and clinicians — as well as what patients and their families can do to advocate for an accurate diagnosis and a faster response to brain health concerns. Watch the full video to learn more about what caregivers and people living with dementia should know about diagnosis. If you loved watching this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/ Follow Being Patient: Twitter:   / being_patient_   Instagram:   / beingpatientvoices   Facebook:   / beingpatientalzheimers   LinkedIn:   / being-patient   Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://www.beingpatient.com/category...#Alzheimers #Dementia #BrainTalk #Diagnosis

On episode 87 of Tritoncast, you'll meet Omar Sabbagh from the UC San Diego men's soccer team. The Calgary native takes us on his soccer journey when he represented Lebanon at the Under 23 Asia Cup over the summer in Saudi Arabia. Omar tells us what it was like training with a new team, what kind of support he got from back home while he was there, and what the first thing he ate was when he got back. He also tells Jeff how he pulls off playing Division I soccer as a chemical engineering major. If you enjoy the show, please subscribe, rate, and write a brief review on your podcast platform of choice. Listen to past episodes anytime on-demand at ucsdtritons.com/podcasts. Go Tritons!

Welcome back to The Trip Report Podcast, a production of Beckley Waves, a Psychedelic Venture Studio.Today, we're speaking with Jonathan Sabbagh, founder of Journey Clinical, a digital health tech company pioneering a collaborative care model for psychedelic-assisted therapy.Journey Clinical was founded in 2021 with the mission of creating a decentralized clinic model that would enable licensed therapists to incorporate ketamine-assisted therapy (KAT) into their practice.Jonathan and his co-founder (and wife) Miriam Barthes interviewed 600 therapists before starting Journey Clinical to understand their biggest pain points and challenges.When it came to KAT, a promising treatment for several mental health conditions, the overwhelming response from the therapists they interviewed was that it's difficult to find medical professionals with whom they can collaborate on care. After all, therapists do not prescribe medications, and most physicians do not do therapy.Thus, connecting therapists with partner prescribers was the core need, and with this insight, the Journey Clinical model was born.As many who are well-steeped in the psychedelic field are aware, KAT is a promising modality for stubborn mental health conditions, especially when paired with psychotherapeutic support. However, the majority of ketamine usage for mental health is as a standalone treatment at specialized clinics. What is missing from this brick-and-mortar care delivery environment is supportive wrap-around care.And in my opinion, this is the promise of technology-enabled support for psychedelic therapies.I have been a fan of the Journey Clinical model since I first met Jonathan and Miriam back in 2021. From the outset, it was clear they had a unique insight and mission.In this episode, we discuss:* Leaving a career in finance to study clinical psychology;* The role of psychotherapy in supporting transformational perspectives;* The importance of therapeutic alliance;* The origin story of Journey Clinical and the pivot from a service provider to a health tech company; and* The Ryan Haight Act Online Pharmacy Consumer Protection Act of 2008.I should also note that Beckley Waves is an investor in Journey Clinical.Listen to the episode on Substack, Spotify, Google or Apple.Credits:* Hosted by Zach Haigney * Produced by Zach Haigney, Erin Greenhouse, and Katelin Jabbari* Find us at thetripreport.com* Follow us on Instagram, Twitter, LinkedIn and YouTubeTheme music by MANCHO Sounds, Mixed and Mastered by Rollin Weary This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thetripreport.com

“What's past is prologue,” Shakespeare informed us. But what if the past is misunderstood? Or misrepresented? What if policy makers are making policies based on false historical narratives?In 1979, host Cliff May went to Iran to report on the revolution that was then underway. Cliff admits that he didn't know much about the country. But neither did most of his colleagues, reporters from around the world who had parachuted in to cover this big story. He was working on a documentary for PBS which had arranged for him to partner with an Iranian producer.  So, at least the producer was knowledgeable, right? Well, yes and no.He was gung-ho for the revolution and an ardent admirer of its leader: the Ayatollah Ruhollah Khomeini. In other words, he was not a truth-seeking journalist but an enthusiastic propagandist. So, this turned out to be a challenging assignment for Cliff.All these many years later, Ray Takeyh – the Hasib J. Sabbagh senior fellow for Middle East studies at the Council on Foreign Relations – is trying to understand and reveal the truth about modern Iranian history.He's well suited to the task: He holds a doctorate in modern history from Oxford University and has served as a senior advisor on Iran at the State Department. He joins Cliff for today's discussion. Also joining: Reuel Marc Gerecht, a former Iranian-targets officer in the Central Intelligence Agency, currently a resident scholar at FDD.

In today's podcast, Jonathan Sabbagh, CEO of Journey Clinical, joins Allison to discuss the history of ketamine in mental health settings, the way ketamine works in your brain, plus how ketamine helps integrate insights. Sponsored by: TherapyNotes®: Use promo code Abundant for 2 months free Heard: Use promo code ABUNDANCE  for 1 month free To learn more about today's guest, visit https://www.abundancepracticebuilding.com/blog.  Why put off success? Join the Abundance Party today & get 40% off your 1st month with coupon code BACKTOSCHOOL: https://abundancepracticebuilding.com/abundanceparty

In this Psychedelic Podcast episode, Paul F. Austin welcomes Jonathan Sabbagh, CEO of Journey Clinical, who shares his mission to integrate FDA-approved psychedelics within the modern therapeutic framework. Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-209-jonathan-sabbagh/ Jonathan highlights the disjointed nature of today's mental health system, where therapists and prescribers lack communication, hindering comprehensive assessments and referrals. He and Paul emphasize Journey Clinical's collaborative care model, streamlining information exchange, and maximizing psychedelic-therapy access through telemedicine innovation. They explore Journey's potential challenges of scalability, therapist training, and insurance coverage for extended sessions. And they consider the balance between state-level decriminalization, psychedelic medicalization, and decentralized access. Join Paul and Jonathan as they imagine a new mental healthcare infrastructure that addresses the growing crisis and reinvents therapeutic care as we know it.   Jonathan Sabbagh: Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to psychedelic-assisted psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During that time, he personally experienced the transformative benefits of plant medicine and ketamine-assisted psychotherapy (KAP). Jonathan's healing journey inspired him to begin formal clinical psychology training at the New School, with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans with depression and anxiety. Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale. Highlights: How Jonathan's mental health & finance background led him to start Journey Clinical. Jonathan's take on co-founding and running Journey Clinical with his wife. The origin story of Journey Clinical and its startup challenges. Exploring Journey's collaborative care model. Investigating Journey's infrastructure solution for psychedelic-assisted therapy. Journey's vetting requirements for network therapists. How the Ryan Haight Act might affect ketamine telehealth access. Journey's decentralized approach to safe and responsible ketamine telemedicine. Integrating FDA-approved psychedelics into the mainstream mental health infrastructure. Jonathan's long-term vision for collaborative mental health care through Journey Clinical. Key Links: Journey Clinical: https://www.journeyclinical.com/ Journey Clinical on Instagram: https://www.instagram.com/journeyclinical Jonathan on Twitter: https://twitter.com/sabbaghjonathan?lang=en Episode Sponsors: Psyched Wellness - use code THIRDWAVE23 to get 15% off. Apollo Neuro - Third Wave listeners get 15% off.

In this special two-episode conference podcast, Joe brings you scientific highlights from the 2022 Society for Neuroscience Meeting. In Part 2 Joe discusses new technologies for comparative connectomics and transcriptomics with Dr. Justus Kebschull, cognitive decline in aging C. elegans with Dr. Rachel Arey and thalamic-cortical circuits and our responsibility for science advocacy with Dr. Ubadah Sabbagh. Episode Guests: Justus Kebschull @JustusKebschull https://www.kebschull-lab.org/ Rachel Arey @AreyLab. https://www.bcm.edu/people-search/rachel-arey-17679 Ubadah Sabbagh@neubadah https://ubadahsabbagh.com/ Episode host: Joe @JWScience Do you enjoy watching the podcast? Feel free to like this episode and follow us to hear more. Max Planck Florida's Neurotransmissions Podcast Website: www.neuropodcast.org Social Media: @MPFneuro Visit https://www.mpfi.org for more information about the Max Planck Florida Institute for Neuroscience

Mr. Longstreet sits down to interview Mr. Sabbagh to talk about the music teachers that have shaped our music programs at University High School over the last 50 years.

In this episode of the Practice of Therapy Podcast, host Gordon Brewer speaks with Jonathan Sabbagh, the Co-Founder, and CEO of Journey Clinical, about the revolutionary practice of using psychedelics in psychotherapy. Sabbagh shares his personal journey with post-traumatic stress disorder, anxiety, depression, and substance abuse and how he found relief through ayahuasca ceremonies. The conversation covers the history and research behind psychedelic therapy, the potential benefits and risks, and the future of integrating this practice into mainstream psychotherapy. Listen in to learn more about the transformative power of psychedelics in mental health treatment. Resources Mentioned In This Episode: Use the promo code "GORDON" to get 2 months of Therapy Notes free Private Practice Resources Join The PsychCraft Network Today! Launch Club The Practice of Therapy Community Focus Groups Jonathan Sabbagh on LinkedIn Journey Clinical Journey Clinical on Instagram Journey Clinical on Facebook

Jonathan is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to Psychedelic-Assisted Psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health, during which he personally experienced the transformative benefits of plant medicine and Ketamine-Assisted Psychotherapy (KAP). Jonathan's personal healing journey inspired him to begin formal clinical psychology training at The New School with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans living with depression and anxiety. Ultimately, Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.In This EpisodeJonathan's website---What's new with The Trauma Therapist Project!The Trauma 5: gold nuggets from my 700+ interviewsThe Trauma Therapist Newsletter: a monthly resource of information and inspiration dedicated to trauma therapists.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5739761/advertisement

Jonathan is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to Psychedelic-Assisted Psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC. After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health, during which he personally experienced the transformative benefits of plant medicine and Ketamine-Assisted Psychotherapy (KAP).  Jonathan's personal healing journey inspired him to begin formal clinical psychology training at The New School with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans living with depression and anxiety. Ultimately, Jonathan's personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.  Learn more at www.JourneyClinical.com. This podcast is sponsored by PCSIntensive.com.

GET TRANSCRIPT AND FULL SHOWNOTES: antiaginghacks.net FullyVital Hair Wellness - Are you interested in getting thicker, fuller and longer hair using natural ingredients? Make sure to check out https://fullyvital.com to get the natural products that stimulate hair follicles in 4 unique ways. Use code ANTIAGINGHACKS to get 15% off your first order. Marwan Sabbagh, M.D. a board-certified neurologist and geriatric neurologist, is one of the nation's leading experts in Alzheimer's and dementia, and has been interviewed by AARP, NPR, Bloomberg, The Wall Street Journal, Prevention and other national media. Dr. Sabbagh is the author of The Alzheimer's Answer, The Alzheimer's Prevention Handbook, and coauthor of Fighting for My Life. His current book is titled Strong Heart, Sharp Mind published in 2022. Topics we discuss on this podcast: 3:10 Dr. Sabbagh's Background What's The Progression Of Alzheimers Disease? 6:10 Biomarker & Genetic Risk of Alzhiemers Disease 7:45 ApoE and it's risk for alzheimers disease 13:20 Why It's Important To Lower Hypertension 17:23 Are statins useful in Alzheimers disease 19:20 Prevention Lifestyle Factor #1: Physical Exercise 22:55 How Alzheimers Progresses In The Brain 25:35 What Are The Best Tests For Detecting Amyloid In The Brain 30:00 Prevention Lifestyle Factor #2: Mediterranean Diet 32:35 Prevention Lifestyle Factor #3: Good Sleep 34:40 Prevention Lifestyle Factor #4: Reduce Stress 36:20 Prevention Lifestyle Factor #5: Cognitive Stimulation 38:50 Prevention Lifestyle Factor #6: Social Connections 42:50 What's The Future Of Alzheimers? 45:40 Where To Find Dr. Sabbagh?

Baraa & Mirna talk all about the foods recommended and not recommended during pregnancy.   Click here to download my healthy recipes ebook with over 20 simple recipes! Want to learn more about nutrition and exercise from a registered dietitian, sports nutritionist, and personal trainer Baraa? Other ways to engage via social: - Follow @baraaelsabbagh on Instagram - Subscribe to Baraa El Sabbagh on Youtube - Visit https://www.baraaelsabbagh.com

6 Effective Ways of Heart Disease Prevention Anyone who wishes to optimize health by protecting the heart and brain must listen to this! Dr. Marwan Sabbagh and Joe Piscatella combine the six most effective principles for heart disease prevention. They unfold valuable heart and brain facts in their new book Strong Heart, Sharp Mind, which are equally beneficial for the prevention of Alzheimer's disease. In a way, they open hope for effective heart disease treatments, dealing with Alzheimer's, and other brain ailments with a multidisciplinary approach. What is good for your heart is good for your brain and ultimately contributes to your overall healthy lifestyle. This episode guides listeners to optimal well-being using a 6-Step Brain-Body Balance Program. In this discussion, he adds that the mechanism that underpins heart disease symptoms considerably overlaps with the symptoms of Alzheimer's. Therefore, aggressively managing the cures for one has two or more benefits. How Is Heart Disease The # 1 Cause Of Death Worldwide? Researchers agreed that cardiovascular arrest, high blood pressure, and cholesterol are risk factors for many other diseases like Alzheimer's. High blood pressure is one of the mechanisms overlapping Alzheimer's and heart disease symptoms, making it the most deadly disease of all time. Dr. Sabbagh believes aggressively managing cholesterol and high blood pressure might considerably help heart disease prevention through natural anti-inflammatory processes. He adds that saturated fats are bad for the brain, which triggers amyloid (an unhealthy protein in the brain), hindering ongoing heart disease treatment. Is High Blood Pressure A Contributor to Heart Disease? National Academy of Sciences, Engineering, and Medicines analyzed the whole shebang, including diet, cognitive stimulation, exercise, health conditions, etc. They came up with their thorough and expert analysis that blood pressure management, mental stimulation, and exercise were the only three things that showed sufficient evidence to recommend them in clinical practices. Several other health organizations are researching, concluding that high blood pressure management is the ultimate risk reduction strategy for the heart and brain. What Are Neurobics? Neurobics are brain exercises that aid in healthy mental activities and prevent severe diseases such as Alzheimer's and heart disease. Dr. Sabbagh suggests Neurobics as a way of simultaneously doing physical activity and cognitive stimulation. In the book, the author outlines the perfect Neurobics that can improve heart function and blood vessel health. Transforming The American Diet into A Healthful Way to Eat According to Berkeley Wellness Letter, Nutrition Actions, and Tufts Newsletter, modest dietary changes can help fight heart disease symptoms. Similarly, one fish meal a week, two berries a week, and two vegetables a day can reduce Alzheimer's disease risk. Managing Alzheimer's with A Good Sleep Regimen Sleep apnea is a huge risk for heart attacks as well as a considerable risk for cognitive decline. Quality sleep is the procedure by which your brain removes the amyloids. That's why Dr. Sabbagh refers to sleep as an easy fix to our mild cognitive illness. Exercise during the daytime, regular meal times, waking up, and going to bed are far more beneficial than sleeping pills. Also, there is a link between inadequate sleep quality, plaque building, and high blood pressure. How Stress Management Is Vital To Defeat Heart Diseases A person's mental health can positively or negatively impact their physical health, and the risk of heart failure may increase with high blood pressure. So, they refer to a phenomenon called 'hippie genetics,' which has secondary benefits in dealing with stress and reducing risks for heart disease. As said, you are more likely to be stress-free if you are physically active and socially connected, leading a healthy lifestyle. Keep your heart pumping and passions alive by knowing what is good for you. If you have people that support you and share the same bond, you are more likely to be mentally healthy. The people who practice cognitive stimulation are the people who exercise and eat right and ultimately lead a healthy lifestyle. However, it is more important to practice mental stimulation even if you have heart disease symptoms or Alzheimer's. The book gives you a great plan to follow that. About the Guest: Marwan Noel Sabbagh, M.D, formerly the Director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, is internationally known for his expertise in the brain and vascular disorders like Alzheimer's and related dementias. For more information about your assessment options for cognitive issues or Alzheimer's, contact Kemper Cognitive Wellness in Cleveland, Ohio. Email: info@kemperwellness.com Website: https://kemperwellness.com/ Phone: (216) 337-1400.

This episode is brought to you by Athletic Greens and ButcherBox. For so long, we've been told that memory loss and dementia are just normal parts of aging.We now know it doesn't have to be that way, and that there are many measures we can proactively take to avoid cognitive decline as we age. Emerging research is helping us look at new ways to treat and even prevent devastating neurological diseases like Alzheimer's and dementia, giving people a newfound sense of hope. In today's episode, I talk with Dr. Marwan Sabbagh, Dr. Richard Isaacson, and Dr. Jay Lombard about the role of genetics in brain disorders, lifestyle habits you can start right now to reduce your risk or reverse symptoms, and why we need to look at bacteria as a cause of neurodegenerative disease. Dr. Marwan Sabbagh is a board-certified neurologist and considered one of the leading experts in Alzheimer's and dementia. He is on the editorial board for the Journal of Alzheimer's Disease and BMC Neurology and is now Editor-in-Chief of Neurology and Therapy. Dr. Sabbagh is the author of The Alzheimer's Answer: Reduce Your Risk and Keep Your Brain Healthy and The Alzheimer's Prevention Cookbook: 100 Recipes to Boost Brain Health. His latest book, Fighting for My Life: How to Thrive in the Shadow of Alzheimer's, is now available.Dr. Richard Isaacson serves as Director of the Center for Brain Health and Director of the Alzheimer's Prevention Clinic (APC) at Florida Atlantic University's Schmidt College of Medicine. He previously served as Director of the APC at the Weill Cornell Memory Disorders Program, Assistant Dean of Faculty Development, and Associate Professor of Neurology at Weill Cornell Medicine and New York-Presbyterian. He remains as Adjunct Associate Professor of Neurology in the Department of Neurology at Weill Cornell. Dr. Jay Lombard is an internationally acclaimed neurologist, author, and keynote speaker specializing in neuroimmunological conditions and medical mysteries. Dr. Lombard integrates biological, psychological, and existential components in his holistic treatment approach. Dr. Lombard's clinical experience revealed an interesting pattern: one patient with ALS also had small-intestine bacterial overgrowth, another had ulcerative colitis, yet another had Crohn's, and so on. He started seeing the connections between these bacterial imbalances and Clostridium difficile, or C. diff, and the link to neurological symptoms. This episode is brought to you by Athletic Greens and ButcherBox.Right now, when you purchase AG1 from Athletic Greens, you will receive 10 FREE travel packs with your first purchase by visiting athleticgreens.com/hyman.When you sign up today, ButcherBox will send you two pounds of sustainably caught, wild Alaskan salmon in your first box for free. To receive this offer, go to ButcherBox.com/farmacy.Full-length episodes of these interviews can be found here:Dr. Marwan SabbaghDr. Richard IsaacsonDr. Jay Lombard See acast.com/privacy for privacy and opt-out information.